Josip Plascevic

Mr. Josip Plascevic

University of Aberdeen, Aberdeen, Aberdeen City, UK
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
MBMaria Anna Bantounou
Maria Anna Bantounou
JPJosip Plascevic
Josip Plascevic
Helen F. GalleyHelen F. Galley
Helen F. Galley
Melatonin, an indoleamine derived from tryptophan and produced in the pineal gland and other tissues

5 May 2023 in Current Urology
Verified
Journal Article
Open access
MBMaria Anna Bantounou
Maria Anna Bantounou
JPJosip Plascevic
Josip Plascevic
LMLewis MacDonald
Lewis MacDonald
MWMan Chun Wong
Man Chun Wong
NONeasa O'COnnell
Neasa O'COnnell
HGHelen F. Galley
Helen F. Galley
Background: Bladder cancer is the 10th most common cancer globally. The majority of bladder cancers are urothelial carcinomas (UCs), which, if locally advanced or metastatic, carry poor long-term prognosis. Cancer cells can evade the immune system by expressing the programmed cell death ligand 1 protein (PD-L1). Programmed cell death ligand 1 protein binds to programmed cell death protein 1 (PD-1) on T cells, inhibiting their antitumor action. Bladder tumor cells also overexpress nectin-4, a cell adhesion polypeptide that contributes to metastasis, worsening prognosis. Current platinum-based chemotherapy treatments are suboptimal. This review aimed to assess novel treatments for locally advanced or metastatic UC that specifically target PD-L1 or nectin-4, namely, the PD-1 inhibitor pembrolizumab and the anti–nectin-4 antibody-drug conjugate enfortumab vedotin (EV). Materials and methods: Relevant English-language peer-reviewed articles and conference abstracts from the last 5 years were identified through MEDLINE and EMBASE database searches. A narrative review was performed, with key results outlined below. Results: Pembrolizumab was demonstrated to be superior to chemotherapy as a second-line treatment for platinum-unresponsive participants in the KEYNOTE-045 trial, resulting in its Food and Drug Administration (FDA) approval. Enfortumab vedotin therapy resulted in superior outcomes compared with chemotherapy in the EV-301 trial, resulting in FDA approval for its use for patients with locally advanced or metastatic UC who had previously undergone treatment with platinum-based chemotherapy and PD-1/PD-L1 inhibitors. Positive preliminary results for pembrolizumab and EV combination therapy have led to FDA approval in patients with locally advanced or metastatic UC who are not eligible for platinum chemotherapy. Conclusions: Pembrolizumab and EV represent novel treatment options for patients with locally advanced or metastatic UC with documented superior outcomes and tolerability as compared with standard chemotherapy.

2 November 2023 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
JPJosip Plascevic
Josip Plascevic
SSShaneel Shah
Shaneel Shah
YTYew-Wei Tan
Yew-Wei Tan

29 November 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
MBMaria Anna Bantounou
Maria Anna Bantounou
PSPanagiotis Sardellis
Panagiotis Sardellis
RTRosa Thuemmler
Rosa Thuemmler
DBDaniel Black Boada
Daniel Black Boada
JKJustyna Kaczmarek
Justyna Kaczmarek
SPSam Philip
Sam Philip
Aim: To investigate the renal safety profile of sotagliflozin, a novel sodium‐glucose co‐transporter‐1 and ‐2 inhibitor, in patients with type 1 diabetes and type 2 diabetes, with or without renal impairment, as well as its efficacy in decreasing the risk of further renal events, with an emphasis on those with previous renal impairment. Methods: Embase, Medline, CENTRAL and Scopus were searched from their inception until 24 April 2023 for randomized controlled trials that reported estimated glomerular filtration rate (eGFR), urinary albumin excretion or composite renal events (CRE). The Cochrane risk of bias 2 tool was used. Mean difference, relative risk (RR) and 95% confidence intervals were estimated (PROSPERO: CRD42023425583). Results: Fourteen studies were included in this review ( n = 17 574 participants; intervention n = 9312, control n = 8262). The median follow‐up was 24.5 (Q1 = 15.25, Q3 = 28) months. Four studies recruited participants with renal impairment; baseline eGFR ranged from 23.8 to 50.5 mL/min/1.73m 2 . The change in eGFR for studies ( n = 6) with a follow‐up of 52 weeks or longer was −1.23 (−1.45, −1.01) mL/min/1.73m 2 . Sotagliflozin did not significantly alter urinary albumin excretion. No change was observed in the risk of CRE ( n = 6 studies; RR = 0.82 [0.61, 1.12]), including in participants with renal impairment. High risk of bias was a limitation of this review. Conclusions: Sotagliflozin did not adversely affect renal function or change the risk of key renal outcomes, including for participants with pre‐existing renal impairment. Therefore, sotagliflozin was safe; however, further research is needed to determine its efficacy in reducing the risk of diabetic kidney disease.

1 January 2024 in Health Services Insights
Verified
Journal Article
Open access
JPJosip Plascevic
Josip Plascevic
JWJoseph Ward
Joseph Ward
RVRussell M. Viner
Russell M. Viner
DHDougal Hargreaves
Dougal Hargreaves
STSteve Turner
Steve Turner
This retrospective population-based analysis assessed variations in urgent healthcare use by children and young people (CYP) across UK nations (England, Scotland and Wales) between 2007 and 2017. The study focused on urgent hospital admissions, short stay urgent admissions (SSUA) and Emergency Department (ED) attendances among CYP aged <25 years, stratified by age groups and Index of Multiple Deprivation (IMD) quintile groups. A linear mixed model was used to assess trends in healthcare activity over time and across deprivation quintiles. Urgent admissions, SSUA and ED attendances increased across all deprivation quintiles in all studied nations. Increasing deprivation was consistently associated with higher urgent healthcare utilisation. In England, the rise in urgent admissions and SSUA for CYP was slower for CYP from the quintile of greatest deprivation compared those from the least deprived quintile (respective mean differences 0.69/1000/y [95% CI 0.53, 0.85] and 0.25/1000/y [0.07, 0.42]), leading to a narrowing in health inequality. Conversely, in Scotland, urgent admissions and SSUA increased more rapidly for CYP from all deprivation quintiles, widening health inequality. Understanding the differences we describe here could inform changes to NHS pathways of care across the UK which slow the rise in urgent healthcare use for CYP.

5 October 2026 in Journal of Reconstructive Microsurgery
Verified
Journal Article
Closed access
JPJosip Plascevic
Josip Plascevic
JLJoey Liang
Joey Liang
TPTara Pillai
Tara Pillai
APAsh Patel
Ash Patel
Robotic-assisted microsurgery offers enhanced precision, tremor filtration, and improved ergonomics, but adoption is limited by undefined learning curves. This systematic review evaluates the learning curve of microvascular anastomosis performed on dedicated robotic platforms. A systematic review was conducted across MEDLINE, Embase, Web of Science, and Cochrane databases (inception to June 2025). Evaluated outcomes included time metrics (anastomosis time, time per stitch), microsurgical skills, and anastomosis quality for the robot-assisted (RA) and hand-sewn (HS) techniques. After screening 6,743 records, 19 studies were included. In preclinical studies (n = 11), mean RA anastomosis time decreased by 18.54 [4.01–47.00] versus 8.43 [0.31–30.00] minutes for HS, although mean final RA time remained longer at the final attempt (20.94 [8.99–36.00] vs. 14.78 [4.58–30.00] minutes). RA time per stitch decreased by a mean of 2.96 [0.83–5.62] minutes compared with 1.58 [− 0.31–4.84] minutes in the HS group. Preclinical microsurgical skill scores improved by 0.99 [0.50–1.63] in the RA group and by 0.76 [− 0.10–1.30] in the HS group. In clinical studies (n = 8), RA anastomosis time was reduced by 18.03 [6.30–37.27] minutes over anastomosis attempts. Preclinical Anastomosis Lapse Index scores were comparable between techniques. Reported immediate patency in clinical settings ranged from 95.66 to 100%. Performance on dedicated robotic platforms improved with practice, but the current evidence did not demonstrate overall superiority over HS technique. In preclinical studies, final RA anastomosis and per-stitch times remained longer, while early anastomosis quality and patency were broadly comparable. Considering added time and platform-associated costs, the clinical settings in which robotic assistance may provide a meaningful benefit remain to be defined. Heterogeneity in models, operators, platforms, and outcome reporting limits definitive characterization of the learning curve. Future studies should standardize learning curve methodology, report complete sequential trajectories, and define clinically relevant proficiency thresholds before integration into credentialing frameworks.